A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

被引：6

作者：

Strati, Paolo ^{[1
]}

Tong, Wei-Gang ^{[1
]}

Vitale, Candida ^{[1
]}

Wierda, William G. ^{[1
]}

O'Brien, Susan ^{[1
]}

Brown, Jennifer R. ^{[2
]}

Weng, Wen-Kai ^{[3
]}

Kipps, Thomas ^{[4
]}

Keating, Michael J. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Stanford Univ, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[4] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 06期

关键词：

CD20; ANTIGEN-EXPRESSION; GM-CSF; MAINTENANCE TREATMENT; LYMPHOMA; THERAPY; IMMUNOTHERAPY; POLYMORPHISMS; MECHANISMS; CELLS;

D O I：

10.3109/10428194.2014.974049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：1878 / 1880

页数：3

共 12 条

[1]

FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia [J].

Farag, SS ;

Flinn, IW ;

Modali, R ;

Lehman, TA ;

Young, D ;

Byrd, JC .

BLOOD, 2004, 103 (04) :1472-1474

[2]

Experience With Rituximab Immunotherapy as an Early Intervention in Patients With Rai Stage 0 to II Chronic Lymphocytic Leukemia [J].

Ferrajoli, Alessandra ;

Keating, Michael J. ;

O'Brien, Susan ;

Cortes, Jorge ;

Thomas, Deborah A. .

CANCER, 2011, 117 (14) :3182-3186

[3]

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network [J].

Hainsworth, JD ;

Litchy, S ;

Barton, JH ;

Houston, GA ;

Hermann, RC ;

Bradof, JE ;

Greco, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1746-1751

[4]

Maloney DG, 1997, BLOOD, V90, P2188

[5]

McLaughlin P, 2005, ANN ONCOL, V16, P68

[6]

GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas [J].

Schuster, Stephen J. ;

Venugopal, Parameswaran ;

Kern, Julie C. ;

McLaughlin, Peter .

LEUKEMIA & LYMPHOMA, 2008, 49 (09) :1681-1692

[7]

Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy [J].

Srock, Stefanie ;

Schriever, Folke ;

Neubauer, Andreas ;

Herold, Michael ;

Huhn, Dieter .

LEUKEMIA & LYMPHOMA, 2007, 48 (05) :905-911

[8]

Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia [J].

Venugopal, P ;

Sivaraman, S ;

Huang, XK ;

Nayini, J ;

Gregory, SA ;

Preisler, HD .

LEUKEMIA RESEARCH, 2000, 24 (05) :411-415

[9]

Voso MT, 2002, HAEMATOLOGICA, V87, P918

[10]

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma [J].

Weng, Wen-Kai ;

Levy, Ronald .

LEUKEMIA & LYMPHOMA, 2009, 50 (09) :1494-1500

← 1 2 →